H B Kuiperij

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2699018/publications.pdf

Version: 2024-02-01

75 papers	2,975 citations	257357 24 h-index	168321 53 g-index
86 all docs	86 docs citations	86 times ranked	5230 citing authors

#	Article	IF	Citations
1	Elevated expression of urokinase plasminogen activator in rodent models and patients with cerebral amyloid angiopathy. Neuropathology and Applied Neurobiology, 2022, 48, e12804.	1.8	0
2	Normal cerebrospinal fluid concentrations of PDGFRÎ² in patients with cerebral amyloid angiopathy and Alzheimer's disease. Alzheimer's and Dementia, 2022, 18, 1788-1796.	0.4	6
3	White Matter Hyperintensities Are No Major Confounder for Alzheimerâ€™s Disease Cerebrospinal Fluid Biomarkers. Journal of Alzheimer's Disease, 2021, 79, 163-175.	1.2	5
4	MFG-E8 (LACTADHERIN): a novel marker associated with cerebral amyloid angiopathy. Acta Neuropathologica Communications, 2021, 9, 154.	2.4	11
5	Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimerâ€™s disease, but not in cerebral amyloid angiopathy. Alzheimer's Research and Therapy, 2021, 13, 160.	3.0	5
6	Identification of cerebrospinal fluid biomarkers for parkinsonism using a proteomics approach. Npj Parkinson's Disease, 2021, 7, 107.	2.5	11
7	A disbalance of matrix metalloproteinases and their inhibitors in the cerebrospinal fluid from patients with cerebral amyloid angiopathy. Alzheimer's and Dementia, 2021, 17, .	0.4	0
8	Apolipoprotein D: a potential biomarker for cerebral amyloid angiopathy. Neuropathology and Applied Neurobiology, 2020, 46, 431-440.	1.8	14
9	Cerebrospinal fluid monocyte chemoattractant protein 1 correlates with progression of Parkinsonâ€™s disease. Npj Parkinson's Disease, 2020, 6, 21.	2.5	17
10	Metabolomics biomarker discovery in cerebrospinal fluid for cerebral amyloid angiopathy. Alzheimer's and Dementia, 2020, 16, e041934.	0.4	0
11	Urokinase plasminogen activator (uPA) as a novel biomarker for cerebral amyloid angiopathy. Alzheimer's and Dementia, 2020, 16, e042512.	0.4	0
12	Neuroleukin: A potential cerebrospinal fluid biomarker for Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e042741.	0.4	0
13	Plateletâ€derived growth factor receptorâ€beta as a potential CSF biomarker for Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e042924.	0.4	0
14	Cerebrospinal fluid myelin basic protein is elevated in multiple system atrophy. Parkinsonism and Related Disorders, 2020, 76, 80-84.	1.1	8
15	Proteomic profiling of striatal tissue of a rat model of Parkinson's disease after implantation of collagenâ€encapsulated human umbilical cord mesenchymal stem cells. Journal of Tissue Engineering and Regenerative Medicine, 2020, 14, 1077-1086.	1.3	4
16	CSF levels of glutamine synthetase and GFAP to explore astrocytic damage in seronegative NMOSD. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 605-611.	0.9	17
17	Disturbed balance in the expression of MMP9 and TIMP3 in cerebral amyloid angiopathy-related intracerebral haemorrhage. Acta Neuropathologica Communications, 2020, 8, 99.	2.4	17
18	Inflammation biomarker discovery in Parkinsonâ€™s disease and atypical parkinsonisms. BMC Neurology, 2020, 20, 26.	0.8	51

#	Article	IF	Citations
19	Reduced Influence of apoE on AÎ²43 Aggregation and Reduced Vascular AÎ²43 Toxicity as Compared with AÎ²40 and AÎ²42. Molecular Neurobiology, 2020, 57, 2131-2141.	1.9	6
20	Serum NFL discriminates Parkinson disease from atypical parkinsonisms. Neurology, 2019, 92, e1479-e1486.	1.5	100
21	Cerebrospinal Fluid Galectin-1 Levels Discriminate Patients with Parkinsonism from Controls. Molecular Neurobiology, 2019, 56, 5067-5074.	1.9	7
22	Biomarkers in cerebrospinal fluid for synucleinopathies, tauopathies, and other neurodegenerative disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 146, 99-113.	1.0	5
23	Plasma AÎ² (Amyloid-Î²) Levels and Severity and Progression of Small Vessel Disease. Stroke, 2018, 49, 884-890.	1.0	27
24	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World Journal of Biological Psychiatry, 2018, 19, 244-328.	1.3	215
25	Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimerâ€™s Disease Cerebrospinal Fluid Biomarkers. Journal of Alzheimer's Disease, 2018, 66, 639-652.	1.2	12
26	Improved Cerebrospinal Fluid-Based Discrimination between Alzheimerâ€™s Disease Patients and Controls after Correction for Ventricular Volumes. Journal of Alzheimer's Disease, 2017, 56, 543-555.	1.2	10
27	Limitations of the hCMEC/D3 cell line as a model for AÎ² clearance by the human bloodâ€brain barrier. Journal of Neuroscience Research, 2017, 95, 1513-1522.	1.3	52
28	MicroRNAs in Cerebrospinal Fluid as Potential Biomarkers for Parkinsonâ€™s Disease and Multiple System Atrophy. Molecular Neurobiology, 2017, 54, 7736-7745.	1.9	119
29	[P4â€“394]: ASSOCIATIONS OF PLASMA AMYLOID BETA LEVELS WITH SEVERITY AND PROGRESSION OF CEREBRAL SMALL VESSEL DISEASE. Alzheimer's and Dementia, 2017, 13, P1479.	0.4	0
30	Multicenter Analytical Validation of AÎ²40 Immunoassays. Frontiers in Neurology, 2017, 8, 310.	1.1	10
31	Validation of microRNAs in Cerebrospinal Fluid as Biomarkers for Different Forms of Dementia in a Multicenter Study. Journal of Alzheimer's Disease, 2016, 52, 1321-1333.	1.2	44
32	Tau Rather than TDP-43 Proteins are Potential Cerebrospinal Fluid Biomarkers for Frontotemporal Lobar Degeneration Subtypes: A Pilot Study. Journal of Alzheimer's Disease, 2016, 55, 585-595.	1.2	41
33	CSF d-serine concentrations are similar in Alzheimer's disease, other dementias, and elderly controls. Neurobiology of Aging, 2016, 42, 213-216.	1.5	40
34	Validation of soluble amyloidâ€Î² precursor protein assays as diagnostic <scp>CSF</scp> biomarkers for neurodegenerative diseases. Journal of Neurochemistry, 2016, 137, 112-121.	2.1	17
35	The utility of Î±-synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature. Biomarkers in Medicine, 2016, 10, 19-34.	0.6	86
36	MicroRNA-29a Is a Candidate Biomarker for Alzheimerâ€™s Disease in Cell-Free Cerebrospinal Fluid. Molecular Neurobiology, 2016, 53, 2894-2899.	1.9	120

#	Article	IF	Citations
37	Cerebrospinal Fluid NrCAM is not a Suitable Biomarker to Discriminate between Dementia Disorders â€“ A Pilot Study. Journal of Alzheimer's Disease, 2015, 46, 605-609.	1.2	4
38	P4-229: Improved CSF-based discrimination between Alzheimer's disease patients and controls after correction for ventricular volumes. , 2015, 11, P868-P868.		0
39	Dickkopfâ€related protein 3 is a potential AÎ²â€associated protein in Alzheimer's Disease. Journal of Neurochemistry, 2015, 134, 1152-1162.	2.1	31
40	CSF Neurofilament Light Chain but not FLT3 Ligand Discriminates Parkinsonian Disorders. Frontiers in Neurology, 2015, 6, 91.	1.1	60
41	A Practical Guide to Immunoassay Method Validation. Frontiers in Neurology, 2015, 6, 179.	1.1	348
42	P1-120: Standardization of a method for diagnostic biomarker validation for neurodegenerative diseases: App assays as example. , 2015, 11, P387-P387.		0
43	Total glutamine synthetase levels in cerebrospinal fluid of Alzheimer's disease patients are unchanged. Neurobiology of Aging, 2015, 36, 1271-1273.	1.5	16
44	Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. Neurobiology of Aging, 2015, 36, 2587-2596.	1.5	30
45	A multifunctional ELISA to measure oxidised proteins: oxPin1 in Alzheimer's brain as an example. BBA Clinical, 2015, 4, 1-6.	4.1	2
46	CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls. Parkinsonism and Related Disorders, 2014, 20, 112-115.	1.1	70
47	Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer's disease but not other dementias. Alzheimer's and Dementia, 2014, 10, 448.	0.4	23
48	MicroRNAs in Alzheimer's disease: differential expression in hippocampus and cell-free cerebrospinal fluid. Neurobiology of Aging, 2014, 35, 152-158.	1.5	220
49	P1-124: BINDING OF THE AB43 PEPTIDE TO APOLIPOPROTEIN E AND ITS ROLE IN CLEARANCE. , 2014, 10, P346-P346.		0
50	P2-117: MICRO-RNAS AS NOVEL BIOMARKERS IN AD: DIFFERENTIAL EXPRESSION IN HIPPOCAMPUS AND IN CELL-FREE CEREBROSPINAL FLUID. , 2014, 10, P514-P514.		0
51	P2-051: THE HCMEC/D3 CELL LINE IS NOT SUITABLE AS A MODEL FOR AÎ² TRANSPORT BY THE HUMAN BLOOD-BRAIN BARRIER. , 2014, 10, P489-P489.		0
52	P4-270: CORRELATIONS OF CSF BIOMARKER LEVELS WITH LATERAL VENTRICULAR CSF VOLUMES. , 2014, 10, P883-P883.		0
53	Levels of HVA, 5-HIAA, and MHPG in the CSF of vascular parkinsonism compared to Parkinsonâ€™s disease and controls. Journal of Neurology, 2013, 260, 3129-3133.	1.8	10
54	Amyloid-Î² oligomer detection by ELISA in cerebrospinal fluid and brain tissue. Analytical Biochemistry, 2013, 433, 112-120.	1.1	103

#	Article	IF	Citations
55	The Diagnostic Value of CSF Amyloid-β₄₃ in Differentiation of Dementia Syndromes. Current Alzheimer Research, 2013, 10, 1034-1040.	0.7	10
56	TDP-43 plasma levels are higher in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 446-451.	2.3	66
57	Diagnosis of progressive supranuclear palsy: can measurement of tau forms help?. Neurobiology of Aging, 2012, 33, 204.e17-204.e18.	1.5	11
58	Detection of tau forms in CSF requires sensitive techniques. Neurobiology of Aging, 2012, 33, 1841.	1.5	10
59	Methods for Analysis of Amyloid-Î² Aggregates. Journal of Alzheimer's Disease, 2012, 28, 735-758.	1.2	62
60	Optimisation of the quantification of glutamine synthetase and myelin basic protein in cerebrospinal fluid by a combined acidification and neutralisation protocol. Journal of Immunological Methods, 2012, 381, 1-8.	0.6	4
61	Inhibition of Î±â€synuclein aggregation by small heat shock proteins. Proteins: Structure, Function and Bioinformatics, 2011, 79, 2956-2967.	1.5	104
62	Detection of elevated levels of Î±-synuclein oligomers in CSF from patients with Parkinson disease. Neurology, 2011, 77, 510-511.	1.5	16
63	Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy. Neurology, 2011, 76, 1443-1443.	1.5	9
64	Do Amyloid Î²-associated Factors Co-deposit with AÎ² in Mouse Models for Alzheimer's Disease?. Journal of Alzheimer's Disease, 2010, 22, 345-355.	1.2	13
65	TDP-43 plasma levels do not differentiate sporadic inclusion body myositis from other inflammatory myopathies. Acta Neuropathologica, 2010, 120, 825-826.	3.9	9
66	Serpina1 (Î±1-AT) is synthesized in the osteoblastic stem cell niche. Experimental Hematology, 2009, 37, 641-647.	0.2	14
67	Biochemistry of the Rapâ€Specific Guanine Nucleotide Exchange Factors PDZâ€GEF1 and â€2. Methods in Enzymology, 2006, 407, 174-186.	0.4	2
68	Activation of FoxO transcription factors contributes to the antiproliferative effect of cAMP. Oncogene, 2005, 24, 2087-2095.	2.6	21
69	The Nrf2-ARE Signalling Pathway: Promising Drug Target to Combat Oxidative Stress in Neurodegenerative Disorders. CNS and Neurological Disorders, 2005, 4, 267-281.	4.3	183
70	Characterisation of PDZ-GEFs, a family of guanine nucleotide exchange factors specific for Rap1 and Rap2. Biochimica Et Biophysica Acta - Molecular Cell Research, 2003, 1593, 141-149.	1.9	75
71	Differential Expression of Tapasin and Immunoproteasome Subunits in Adenovirus Type 5- Versus Type 12-transformed Cells. Journal of Biological Chemistry, 2003, 278, 139-146.	1.6	16
72	Cyclic AMP induces integrin-mediated cell adhesion through Epac and Rap1 upon stimulation of the Î²2-adrenergic receptor. Journal of Cell Biology, 2003, 160, 487-493.	2.3	248

#	Article	IF	Citations
73	Protein kinase C-$alpha; is an upstream activator of the I$kappa;B kinase complex in the TPA signal transduction pathway to NF-$kappa;B in U2OS cells. Cellular Signalling, 2000, 12, 759-768.	1.7	81
74	cDNA micro array identification of a gene differentially expressed in adenovirus type 5- versus type 12-transformed cells. FEBS Letters, 2000, 487, 151-155.	1.3	13
75	Domains of Glycoprotein H of Herpes Simplex Virus Type 1 Involved in Complex Formation with Glycoprotein L. Virology, 1999, 261, 96-105.	1.1	9